Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Pancreatic cancer.

Publication ,  Conference
Li, D; Xie, K; Wolff, R; Abbruzzese, JL
Published in: Lancet
March 27, 2004

Pancreatic cancer remains a major unsolved health problem, with conventional cancer treatments having little impact on disease course. Almost all patients who have pancreatic cancer develop metastases and die. The main risk factors are smoking, age, and some genetic disorders, although the primary causes are poorly understood. Advances in molecular biology have, however, greatly improved understanding of the pathogenesis of pancreatic cancer. Many patients have mutations of the K-ras oncogene, and various tumour-suppressor genes are also inactivated. Growth factors also play an important part. However, disease prognosis is extremely poor. Around 15-20% of patients have resectable disease, but only around 20% of these survive to 5 years. For locally advanced, unresectable, and metastatic disease, treatment is palliative, although fluorouracil chemoradiation for locally advanced and gemcitabine chemotherapy for metastatic disease can provide palliative benefits. Despite pancreatic cancer's resistance to currently available treatments, new methods are being investigated. Preoperative chemoradiation is being advocated, with seemingly sound reasoning, and a wider role for gemcitabine is being explored. However, new therapeutic strategies based on the molecular biology of pancreatic cancer seem to hold the greatest promise.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

March 27, 2004

Volume

363

Issue

9414

Start / End Page

1049 / 1057

Location

England

Related Subject Headings

  • Risk Factors
  • Pancreatic Neoplasms
  • Male
  • Humans
  • General & Internal Medicine
  • Gemcitabine
  • Drug Therapy, Combination
  • Deoxycytidine
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, D., Xie, K., Wolff, R., & Abbruzzese, J. L. (2004). Pancreatic cancer. In Lancet (Vol. 363, pp. 1049–1057). England. https://doi.org/10.1016/S0140-6736(04)15841-8
Li, Donghui, Keping Xie, Robert Wolff, and James L. Abbruzzese. “Pancreatic cancer.” In Lancet, 363:1049–57, 2004. https://doi.org/10.1016/S0140-6736(04)15841-8.
Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. In: Lancet. 2004. p. 1049–57.
Li, Donghui, et al. “Pancreatic cancer.Lancet, vol. 363, no. 9414, 2004, pp. 1049–57. Pubmed, doi:10.1016/S0140-6736(04)15841-8.
Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004. p. 1049–1057.
Journal cover image

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

March 27, 2004

Volume

363

Issue

9414

Start / End Page

1049 / 1057

Location

England

Related Subject Headings

  • Risk Factors
  • Pancreatic Neoplasms
  • Male
  • Humans
  • General & Internal Medicine
  • Gemcitabine
  • Drug Therapy, Combination
  • Deoxycytidine
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents